ADVISORY, Nov. 01, 2016 (GLOBE NEWSWIRE) --
What:
Titan Pharmaceuticals, Inc. (Nasdaq:TTNP), a specialty pharmaceutical company developing proprietary therapeutics for
the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform, will visit the
Nasdaq MarketSite in Times Square.
In honor of the occasion, Titan President and CEO Sunil Bhonsle, will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Wednesday, November 2, 2016 – 3:45 p.m. to 4:00 p.m. ET
Titan Contact:
Stephen Kilmer
(650) 989-2215
skilmer@titanpharm.com
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please
visit our Facebook page:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your
choice.
About Titan Pharmaceuticals
Titan Pharmaceuticals Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a specialty pharmaceutical company
developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product candidate
is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence.
Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels
of medication for three months or longer. Titan has granted commercial rights for the U.S. and Canada for Probuphine to Braeburn
Pharmaceuticals. Approved by the FDA in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to
provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura
technology has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease
and hypothyroidism, where maintaining consistent, around the clock blood levels of medication may benefit the patient and improve
medical outcomes. For more information about Titan, please visit www.titanpharm.com.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public
company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and
execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed
companies with a market value of approximately $9.3 trillion and nearly 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
-NDAQA-
